Trials
NEW YORK, NY: NEW YORK, NY -- (Marketwired) -- 04/09/13 -- PropThink.com, a leading healthcare-focused provider of investment research and analysis, will host a conference call with Intellectual Property attorney ...
TUSTIN, CA: Meaningful Improvement in Median Overall Survival in Patients With Second-Line NSCLC Supports Advancing Bavituximab Into Phase III Development; Contract Manufacturing Revenue Tops $17 Million for Nine ...
BRISBANE, AUSTRALIA: Key US Patent Granted for HyACT Targeted Chemotherapy in Colon Cancer; Extends Monopoly Rights for HA-Irinotecan as Well as Additional Colon Cancer Chemotherapies ...
: The German clinical contract research organization (CRO), ICRC-Weyer GmbH, is extending their Medical Writing Services with specialized Pharmacovigilance Writing, a comprehensive solution for regulato ...
MANCHESTER, NH: PAZ320 Demonstrated 40 Percent Reduction of Post-Meal Blood Glucose Without Serious Adverse Events ...
BEVERLY, MA: BEVERLY, MA -- (Marketwire) -- 01/24/13 -- Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to tr ...
SEATTLE, WA: SEATTLE, WA -- (Marketwire) -- 01/18/13 -- (NASDAQ: ATOS) announced today that Kyle Guse, chief financial officer, general counsel and secretary, will present at the NINE 2013 - Noble Financial Capi ...
: The Berlin-based clinical contract research organization (CRO) ICRC-Weyer GmbH is adapting a process of integrating medical review procedures into Pharmacovigilance risk management, a method that will ...
PARSIPPANY, NJ: CHAMPION PHOENIX Trial Meets Protocol-Specified Predefined Efficacy Endpoint; Intravenous Bolus and Infusion of Cangrelor Provided Statistically Significant Improvement in Ischemic Events at 48 Hours ...
BOSTON, MA: Accomplished Executive to Drive Strategies That Support Precision and Accuracy of Clinical Trial Data ...
: ICRC-Weyer GmbH, a clinical contract research organization (CRO) based in Berlin, Germany, has released its review of the year 2012, stating it has been a successful and exciting 12 months for everybo ...
TUSTIN, CA: Contract Manufacturing Revenue Expected to Exceed $18 Million for Fiscal Year 2013; Company Reaches Agreement With FDA on Pivotal Phase III Clinical Trial Design for Cotara; Multiple Bavituximab Clini ...
BOSTON, MA: WCC President Rick Walovitch to Present on Central Review for Trials With Subjective Endpoints at CBI Bio/Pharmaceutical Imaging Forum on December 11th ...
LOS ALTOS, CA: LOS ALTOS, CA -- (Marketwire) -- 12/05/12 -- Pherin Pharmaceuticals announced today that a Phase II clinical trial showed that its proprietary compound PH94B demonstrated significant benefits in the ...
CARLSBAD, CA: CARLSBAD, CA -- (Marketwire) -- 12/04/12 -- International Stem Cell Corporation (OTCQB: ISCO) () ("ISCO" or "the Company"), a California-based biotechnology company focused on the ...
BOSTON, MA: Leverages Established Clinical Infrastructure to Facilitate Real-Time Global Site Support ...
ATLANTA, GA: Special Track for Principal Investigators Offers CME Credits ...
